It’s Not Just the Money: Why Consumers Do Not Purchase Pharmacist-Provided Services


The reimbursement model for pharmaceutical care remains a barrier to successful widespread implementation of pharmacist-provided services. In some instances, community pharmacists have been successful in obtaining direct compensation for services from patients; however, evidence suggests that lack of patient demand for pharmacist-services may ultimately undermine the campaign for widespread third-party payment. The purpose of this study is to conduct a secondary analysis of data indicating consumer/patients’ rationale for not purchasing pharmacist-provided disease management services when offered the opportunity to do so in community pharmacies. Our review of the data indicates that while financial concerns are clearly important in consumer demand for pharmacist-provided services, other considerations exist. The consumer/patient belief that pharmacist-provided services are duplicative or that these services are not needed are significant barriers to overcome. Intensive education and marketing campaigns are needed to sway consumer opinion on the value of pharmacist-provided services.

Share and Cite:

Freeman, P. , Jones, M. and Blumenschein, K. (2014) It’s Not Just the Money: Why Consumers Do Not Purchase Pharmacist-Provided Services. Pharmacology & Pharmacy, 5, 570-576. doi: 10.4236/pp.2014.56067.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Carroll, N.V., Miederhoff, P.A. and Waters, L.W. (1996) Profitability, Third-Party Reimbursement, and Access to Community Pharmacies. Clinical Therapeutics, 118, 703-715.
[2] Anon (2005) Trend of the Month: Pharmacy Reimbursement Continues to Drop. Drug Benefit Trends, 17, 8.
[3] NACDS Statement on Medicaid Prescription Drugs: Examining Options for Payment Reform. Presented to the Hearing of the House Energy and Commerce Committee Subcommittee on Health, 2005.
[4] Willink, D.P. and Isetts, B.J. (2005) Becoming “Indispensable”: Developing Innovative Community Pharmacy Practices. Journal of the American Pharmacists Association, 45, 376-389.
[5] Doucette, W.R., Kreling, D.H., Schommer, J.C., Gaither, C.A., Mott, D.A. and Pedersen, C.A. (2006) Evaluation of Community Pharmacy Service Mix: Evidence from the 2004 National Pharmacist Workforce Study. Journal of the American Pharmacists Association, 46, 348-355.
[6] Giberson, S., Yoder, S. and Lee, M.P. (2011) Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. Office of the Chief Pharmacist, U.S. Public Health Service.
[7] Ganther, J.M. (2002) Third-Party Reimbursement for Pharmacist Services: Why Has It Been So Difficult to Obtain and Is It Really the Answer for Pharmacy. Journal of the American Pharmacists Association, 42, 875-879.
[8] Beatty, S.J., Rodis, J.L., Bellebaum, K.L. and Mehta, B.H. (2006) Community and Ambulatory Pharmacy: Evaluation of Patient Care Services and Billing Patterns before Implementation of Medicare Part D. Journal of the American Pharmacists Association, 46, 707-714.
[9] Beatty, S.J., McCormick, K.M., Beale, D.J., Bruggeman, A.M., Rodis, J.L., Mehta, B.H. and Bennett, M.S. (2012) Current Trends in Outpatient Pharmacy Services and Billing. Journal of the American Pharmacists Association, 52, 154-160.
[10] Bernsten, C., Andersson, K., Gariepy, Y. and Simoens, S. (2010) A Comparative Analysis of Remuneration Models for Pharmaceutical Professional Services. Health Policy, 95, 1-9.
[11] Skelton, J.B. (2011) Pharmacist-Provided Immunization Compensation and Recognition: White Paper Summarizing APhA/AMCP Stakeholder Meeting. Journal of the American Pharmacists Association, 51, 704-712.
[12] Federal Register/Vol. 70, No. 18/Friday, January 28, 2005/Rules and Regulations.
[13] Snella, K.A., Trewyn, R.R., Hansen, L.B., et al. (2004) Pharmacist Compensation for Cognitive Services: Focus on the Physician Office and Community Pharmacy. Pharmacotherapy, 24, 372-388.
[14] Schafermeyer, K. (1999) The Impact of Managed Care on Pharmacy Practice. In: Navarro, R., Ed., Managed Care Pharmacy Practice, Aspen Publishers, Gaithersburg, 451-473.
[15] Bluml, B.M., McKenney, J.M. and Cziraky, M.J. (2000) Pharmaceutical Care Services and Results in Project Impact: Hyperlipidemia. Journal of the American Pharmacists Association, 40, 157-165.
[16] Bennett, M.S., Blank, D., Bopp, J., et al. (2000) Strategies to improve compensation for pharmaceutical care services. Journal of the American Pharmacists Association, 40, 747-755, 870-872.
[17] Johannesson, M., Johansson, P.-O. and Jönsson, B. (1992) Economic Evaluation of Drug Therapy: A Review of the Contingent Valuation Method. PharmacoEconomics, 1, 325-337.
[18] Woelfel, J.A., Carr-Lopez, S.M., Delos Santos, M., Bui, A., Patel, R.A., Walberg, M.P. and Galal, S.M. (2014) Assessing Medicare beneficiaries’ Willingness-to-Pay for Medication Therapy Management Services. The Consultant Pharmacist, 29, 104-109.
[19] Schuh, M.J. and Droege, M. (2008) Cognitive Services Provided by Pharmacists: Is the Public Willing to Pay for Them? The Consultant Pharmacist, 23, 223-230.
[20] Friedrich, M., Zgarrick, D., Masood, A. and Montuoro, J. (2010) Patients’ Needs and Interests in a Self-Pay Medication Therapy Management Service. Journal of the American Pharmacists Association, 50, 72-77.
[21] Blumenschein, K., Johannesson, M. and Yokoyama, K. (2001) Hypothetical vs. Real Willingness to Pay in the Health Sector: Results from a Field Experiment. Journal of Health Economics, 20, 441-457.
[22] Blomquist, G.C., Blumenschein, K. and Johannesson, M. (2009) Eliciting Willingness to Pay without Bias Using Follow-Up Certainty Statements: Comparison between Probably/Definitely and a 10-Point Certainty Scale. Environmental and Resource Economics, 43, 473-502.
[23] Blumenschein, K., Blomquist, G.C., Johannesson, M., Horn, N. and Freeman, P. (2008) Eliciting Willingness to Pay without Bias: Evidence from a Field Experiment. The Economic Journal, 118, 114-137.
[24] Carson, R.T. (2000) Contingent Valuation: A User’s Guide. Environmental Science and Technology, 34, 1413-1418.
[25] Wang, J. and Hong, S.H. (2012) Contingent Valuation and Pharmacists’ Acceptable Levels of Compensation for Medication Therapy Management Services. Research in Social & Administrative Pharmacy.
[26] Global Initiative for Asthma (GINA) (2004) Global Strategy for Asthma Management and Prevention. National Institute of Health, Bethesda, Publication No. 02-3659.
[27] Basagaa, X., Sunyer, J., Kogevinas, M., et al. (2004) Socioeconomic Status and Asthma Prevalence in Young Adults. American Journal of Epidemiology, 160, 178-188.
[28] Robbins, J.M., Vaccarino, V., Zhang, H., et al. (2001) Socioeconomic Status and Type 2 Diabetes in African American and Non-Hispanic White Women and Men: Evidence from the Third National Health and Nutrition Examination Survey. American Journal of Public Health, 91, 76-83.
[29] Connolly, V., Unwin, N., Sherriff, P., et al. (2000) Diabetes Prevalence and Socioeconomic Status: A Population Based Study Showing Increased Prevalence of Type 2 Diabetes Mellitus in Deprived Areas. Journal of Epidemiology & Community Health, 54, 173-177.
[30] Kradjan, W.A., Schulz, R., Christensen, D.B., et al. (1999) Patients’ Perceived Benefit from and Satisfaction with Asthma-Related Pharmacy Services. Journal of the American Pharmacists Association, 39, 658-666.
[31] Smith, M., Cannon-Breland, M.L. and Spiggle, S. (2013) Consumer, Physician, and Payer Perspectives on Primary Care Medication Management Services with a Shared Resource Pharmacist Network. Research in Social & Administrative Pharmacy.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.